advanced search

EXPERT VIEW

EXPERT VIEW
MASTERING COMMERCIAL MANUFACTURING FOR STERILE INJECTABLES
Jennifer Gattari delves into what is required to succeed at the commercial phase of sterile injectable manufacturing, going on to explore the challenges that companies can expect and the critical strategies that can help ensure a smooth and scalable journey to market.
EXPERT VIEW
PRESSURE ON THE SUPPLY CHAIN: TARIFFS, REGULATIONS AND TRANSPARENCY
Jacob Tyson and Jon Lawrence consider the changes in the regulatory landscape for medical device manufacturers; the critical role that suppliers, distributors and importers play in ensuring effective post-market surveillance; and the technologies that companies are adopting to support traceability solutions.
HARNESSING X-RAY AND AI FOR A NEW ERA OF QUALITY CONTROL
EXPERT VIEW
Dr Richard Parmee
HARNESSING X-RAY AND AI FOR A NEW ERA OF QUALITY CONTROL
Dr Richard Parmee discusses the multitudinous applications of X-ray inspection technology for high-speed pharmaceutical production lines, covering the value of introducing artificial intelligence and machine learning techniques to enhance detection and improve safety.
NAVIGATING SEMICONDUCTOR LIFECYCLE CHALLENGES IN MEDTECH: A STRATEGIC SHIFT TOWARDS ASICs
EXPERT VIEW
Andy Kelly
NAVIGATING SEMICONDUCTOR LIFECYCLE CHALLENGES IN MEDTECH: A STRATEGIC SHIFT TOWARDS ASICs
Andy Kelly considers the evolution of semiconductor technology and the impact of the release of new and upgraded components. This article discusses how strategic decisions during the early stages of product design can determine the future viability of a medical device and considers the cost savings offered by application-specific integrated circuits through a reduction in the number of components required.
CONNECTED BUT PROTECTED – SECURELY CONNECTING DRUG DELIVERY DEVICES
EXPERT VIEW
Dr Joachim Wilke
CONNECTED BUT PROTECTED – SECURELY CONNECTING DRUG DELIVERY DEVICES
Dr Joachim Wilke discusses wireless connectivity in novel drug delivery devices, highlighting the possibilities for improved patient outcomes and care, the associated security risks, as well as examining the wide range of cyber security solutions and standards to mitigate these issues.
SMART ENOUGH: DESIGNING DRUG DELIVERY DEVICES THAT PUT PATIENTS FIRST
EXPERT VIEW
Andy Pidgeon
SMART ENOUGH: DESIGNING DRUG DELIVERY DEVICES THAT PUT PATIENTS FIRST
Andy Pidgeon  challenges the assumption that more advanced technology is always better, re-examining the design approach to connected autoinjectors from the patient perspective and highlighting the value of simplicity and usability – digging into the idea that, by investigating the real-world needs of patients, drug delivery device designers can ensure that their devices are serving those needs, rather than creating unnecessary new challenges for users.
A STICKY ISSUE: TRANSFORMING OILY PLANT EXTRACTS INTO SOLID ORAL DOSAGE FORMS
EXPERT VIEW
Dr Maj-Britt Cepok
A STICKY ISSUE: TRANSFORMING OILY PLANT EXTRACTS INTO SOLID ORAL DOSAGE FORMS
Dr Maj-Britt Cepok discusses the increasing prevalence of plant extracts in the oral solid dosage market, considering how the common physical properties of these ingredients can both provide benefits and pose a challenge to formulators looking to capitalise on this rapidly growing market segment.
RETHINKING GLP-1 DELIVERY DEVICES: DESIGNING FOR USERS BEYOND DIABETES
EXPERT VIEW
Dan Lock
RETHINKING GLP-1 DELIVERY DEVICES: DESIGNING FOR USERS BEYOND DIABETES
Dan Lock explores how the experiences and motivations of individuals using glucagon-like peptide 1 drugs for weight loss may differ from those managing diabetes or heart disease.
THE PFAS PROBLEM: IMPROVING SUSTAINABILITY WITH NONWOVEN INNOVATION
EXPERT VIEW
Jack Eaton
THE PFAS PROBLEM: IMPROVING SUSTAINABILITY WITH NONWOVEN INNOVATION
Jack Eaton considers the current landscape for drug delivery and packaging, and how developments and research in nonwoven and fibrous materials can help businesses address the problem of per- and polyfluoroalkyl substances.
AI, DATA AND PARTNERSHIPS: THE BUILDING BLOCKS FOR MORE SUSTAINABLE CLINICAL TRIALS
EXPERT VIEW
Sas Maheswaran
AI, DATA AND PARTNERSHIPS: THE BUILDING BLOCKS FOR MORE SUSTAINABLE CLINICAL TRIALS
Sas Maheswaran discusses how artificial intelligence, data and strategic partnerships can make clinical trials more sustainable – both financially and environmentally.
BLISTERS, BONDS AND BIOLOGICS: HOW TO ACHIEVE STABILITY OF DRY POWDER BIOLOGICS
EXPERT VIEW
Dr Heather Jameson
BLISTERS, BONDS AND BIOLOGICS: HOW TO ACHIEVE STABILITY OF DRY POWDER BIOLOGICS
Heather Jameson and Dave Farrow cover the challenging formulation science required to develop a viable dry powder aerosol and examine the inhaler device requirements necessary to protect the formulation throughout its shelf life while also ensuring consistent, high-performance delivery.
SHIELDED THERAPEUTICS: COULD POLYMERIC NANOPARTICLES SAFEGUARD A NEW GENERATION OF INHALED DRUGS?
EXPERT VIEW
Kamaal de Silva
SHIELDED THERAPEUTICS: COULD POLYMERIC NANOPARTICLES SAFEGUARD A NEW GENERATION OF INHALED DRUGS?
Kamaal de Silva and Ethan Miller provide an overview of the benefits of polymeric nanoparticles in pulmonary drug delivery and their potential to overcome key challenges in respiratory medicine, while summarising the range of pulmonary delivery devices that could benefit from their use.
MEETING THE DEMAND FOR PATIENT CENTRICITY WITH NASAL SPRAY REPOSITIONING
EXPERT VIEW
Eric Kaneps
MEETING THE DEMAND FOR PATIENT CENTRICITY WITH NASAL SPRAY REPOSITIONING
Eric Kaneps discusses key emerging drug delivery trends poised to help the pharmaceutical industry meet the growing demand for patient-centric solutions, with a particular focus on nasal drug delivery, as the nasal spray repositioning of existing drugs offers a range of benefits, including rapid onset of action, improved bioavailability and ease of administration for patients.
GENE THERAPY IN OPHTHALMOLOGY: ADVANCES AND CHALLENGES
EXPERT VIEW
Dr Joe Batley
GENE THERAPY IN OPHTHALMOLOGY: ADVANCES AND CHALLENGES
Joe Batley and Lorna Barron provide an overview of the latest cutting-edge ophthalmic delivery methods and discuss possible future developments.
REVOLUTIONISING EYE CARE: THE POTENTIAL OF ANTISENSE OLIGONUCLEOTIDES
EXPERT VIEW
Binbin Tian
REVOLUTIONISING EYE CARE: THE POTENTIAL OF ANTISENSE OLIGONUCLEOTIDES
Binbin Tian discusses antisense oligonucleotides and considers their potential as treatments for genetic and multifactorial ophthalmic diseases previously considered untreatable. The article considers how these therapies function as treatments, their current state of development, challenges in their delivery and the evolving regulatory landscape
DRUG DELIVERY TRENDS FOR 2025
EXPERT VIEW
Tom Oakley
DRUG DELIVERY TRENDS FOR 2025
Tom Oakley and Alex Vasiev look back at how the trends anticipated for 2024 played out in reality and look forward to four major trends expected to influence the drug delivery industry in 2025.
FROM PLATFORM TO PRODUCT: ACCELERATING TIME-TO-MARKET FOR PLATFORM TECHNOLOGIES
EXPERT VIEW
Fran Pencliffe
FROM PLATFORM TO PRODUCT: ACCELERATING TIME-TO-MARKET FOR PLATFORM TECHNOLOGIES
Fran Pencliffe explores the benefits of platform devices for parenteral delivery and outlines the challenges, risks and best practices when bringing a combination product to market in this way.
ELEVATING DIGITAL PATIENT SUPPORT: NOTHING MATTERS UNLESS IT CHANGES BEHAVIOUR
EXPERT VIEW
Dr Ben Cox
ELEVATING DIGITAL PATIENT SUPPORT: NOTHING MATTERS UNLESS IT CHANGES BEHAVIOUR
Ben Cox, Thomas Grant and Lara Zaki discuss the role of behaviour design in onboarding for self-injection devices and how a robust and balanced framework can enhance the patient experience, reduce injection errors and promote safe and effective use.
NEXT-GENERATION AUTOINJECTORS: BALANCING PATIENTS, PHARMA, PAYERS AND PLANET
EXPERT VIEW
David Latham
NEXT-GENERATION AUTOINJECTORS: BALANCING PATIENTS, PHARMA, PAYERS AND PLANET
David Latham, Matthew Allen and Charlie Dean use a case study of a reusable electromechanical autoinjector to outline the novel product development approach needed to achieve better outcomes for patients, pharma, payers and the planet.
CUSTOM INTEGRATED CIRCUITS ENABLING ADVANCEMENTS IN IMPLANTABLE DRUG DELIVERY SYSTEMS
EXPERT VIEW
Dr Asheesh Divetia
CUSTOM INTEGRATED CIRCUITS ENABLING ADVANCEMENTS IN IMPLANTABLE DRUG DELIVERY SYSTEMS
Asheesh Divetia looks at how custom electronics are advancing implantable drug delivery systems – with precise drug administration, seamless connectivity to other devices and real-time monitoring of drug levels and patient responses.
EFFICIENTLY PRODUCING INJECTABLES IN SMALL BATCHES
EXPERT VIEW
Klaus Brinkrode
EFFICIENTLY PRODUCING INJECTABLES IN SMALL BATCHES
Klaus Brinkrode and Ulrik Keldke discuss industry challenges in injectable production – and how to produce small batches of injection devices efficiently.
TRACE ANALYTICAL CONSIDERATIONS WHEN REFORMULATING pMDIS WITH NEXT-GENERATION LOW-GWP PROPELLANT SYSTEMS
EXPERT VIEW
Mark Parry
TRACE ANALYTICAL CONSIDERATIONS WHEN REFORMULATING pMDIS WITH NEXT-GENERATION LOW-GWP PROPELLANT SYSTEMS
Mark Parry, John McLaughlin and Tino Otte discuss the necessary studies required to understand the nitrosamine formation and leachables profiles of new pMDI propellants with lower global warming potentials as part of the pharmaceutical industry’s drive to reduce its emissions and environmental impact.
ENVIRONMENTAL BENEFITS OF BEDSIDE IONIC NITRIC OXIDE GENERATION
EXPERT VIEW
David Webster
ENVIRONMENTAL BENEFITS OF BEDSIDE IONIC NITRIC OXIDE GENERATION
David Webster and Mark Rimkus consider the environmental impact of traditional high-pressure storage systems for nitric oxide and highlight the benefits associated with bedside ionic generation.
FUTURE TRENDS FOR NOVEL INJECTABLE DRUG DELIVERY
EXPERT VIEW
Chris Hurlstone
FUTURE TRENDS FOR NOVEL INJECTABLE DRUG DELIVERY
Chris Hurlstone looks at the increasing demand for novel injectable devices and summarises the areas we can expect to see significant development activities in injectable technologies.
DEFINING HIGH-VISCOSITY, LARGE-VOLUME DRUG DELIVERY SYSTEMS
EXPERT VIEW
Kyle Toole
DEFINING HIGH-VISCOSITY, LARGE-VOLUME DRUG DELIVERY SYSTEMS
Kyle Toole, Blair Hutton and James McLusky discuss the value that mathematical modelling can provide in the early stages of injectable drug delivery device development, especially when coupled with appropriate empirical testing in a laboratory setting.
NAVIGATING THE AI REVOLUTION IN THE MEDICAL DEVICES SECTOR: BETWEEN INNOVATION AND REGULATION
EXPERT VIEW
Timothy Bubb
NAVIGATING THE AI REVOLUTION IN THE MEDICAL DEVICES SECTOR: BETWEEN INNOVATION AND REGULATION
Timothy Bubb discusses the potential impact of artificial intelligence and machine learning on the healthcare and drug delivery industries, with an overview of the differing regulatory approaches taken by the EU, US FDA and UK MHRA towards this novel area of digital health.
Top